Domestic marketing status and drug purchase guide of Talazoparib

Talazoparib As a PARP inhibitor developed by Pfizer , it has been widely used overseas to treat BRCA mutated breast cancer. In recent years, this drug has also entered the Chinese market and has become a much-anticipated member of the targeted tumor drugs. There have been some latest developments regarding its domestic launch and drug purchase channels.

The original drug of talazoparib has been officially approved for marketing in China. However, due to its short time on the market, its medical insurance policy and price system are still in the stage of being gradually clarified. At present, a unified national medical insurance reimbursement scope has not been announced, so patients often face a high financial burden when actually paying. According to market feedback, the reference price of the Hong Kong version of the original drug is about 50,000 yuan per box of 1mg*30 pills, which is still high for most patients.

In terms of drug purchase channels, domestic patients can obtain them through a variety of channels. One is to purchase original drugs through hospital pharmacies under the guidance of a doctor's prescription. This is also the safest and most controllable way. However, because some hospitals have not yet fully distributed the drug, some patients may need to be transferred to designated cancer centers with better drug accessibility. Another way is cross-border drug purchase. Some patients purchase drugs overseas through compliant channels, but special attention must be paid to avoid purchasing through informal channels to prevent the risk of counterfeit or smuggled drugs.

In addition to price and channels, patients should also pay attention to medication guidance during the drug purchase process. As a prescription drug, talazoparib should be used after a doctor's evaluation, especially in conjunction with the BRCA gene test results to determine whether it is suitable. At the same time, blood and liver and kidney functions need to be monitored regularly during medication to prevent safety risks caused by severe bone marrow suppression or drug accumulation.

Overall, the domestic launch of talazoparib has brought new hope to breast cancer patients, but it is still necessary to pay attention to formal channels and medical guidance when purchasing the drug to avoid increasing risks due to opaque information.

Reference materials:https://www.talzenna.com/